Authors proposed an increased TGF-β1 signaling, which is, among CCL2, IL6 and others, a central SASP component, as the cause of p53 activation in NAFLD/NASH [77]. Here, TP53 is linked to metabolic dysfunction-associated steatotic liver disease.